Drug Type Autologous CAR-T |
Synonyms- |
Target |
Action modulators |
Mechanism BAFF modulators(B-cell-activating factor/B lymphocyte stimulator modulators), CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse Large B-Cell Lymphoma | Phase 1 | China | 30 May 2024 | |
Pre B-cell acute lymphoblastic leukemia | Phase 1 | China | 30 May 2024 | |
Neuromyelitis Optica | Phase 1 | China | 15 Apr 2024 | |
Scleroderma, Systemic | Phase 1 | China | 15 Apr 2024 | |
Systemic Lupus Erythematosus | Phase 1 | China | 15 Apr 2024 |